Results 51 to 60 of about 1,093,936 (286)
Chronic Viral Hepatitis in Human Immunodeficiency Virus-infected Patients
, 2016 Infectious diseases physicians taking care of human immunodeficiency virus-infected patients should investigate for the presence of chronic hepatitis caused by hepatitis B and hepatitis C virus infections.
SİLİ, ULUHAN, KORTEN, VOLKAN
core +2 more sources
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley +1 more source
Diversity of human astroviruses in Germany 2018 and 2019
Virology Journal, 2022 Aim of this study was to investigate the molecular diversity of human astroviruses (HAstV) in Germany. A follow-up study was performed with human stool samples collected in 2018–2019, which were genotyped retrospectively.
Sandra Niendorf +3 more
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective Ambulatory care–sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin +7 more
wiley +1 more source
Fast Facts:\ue2\u20ac\ua2 People with HIV infection are affected disproportionally by viral hepatitis.\ue2\u20ac\ua2 Nearly 75% of people with HIV who report a history of injection drug use also are infected with hepatitis C virus (HCV).\ue2\u20ac\ua2 ...
core +2 more sources
2020 National viral hepatitis progress report [PDF]
The National Viral Hepatitis Progress Report provides information on ten data indicators, providing an objective way to assess progress toward achieving key viral hepatitis goals.Publication date from document properties.NationalProgressReport2020 ...
core
Real‐World Safety of Concomitant Colchicine and Statin Therapy
Arthritis Care &Research, EarlyView.Objective This study aimed to evaluate the risk of clinically meaningful muscle‐ and liver‐related outcomes associated with concomitant colchicine–statin therapy in a real‐world setting, and to determine whether concomitant therapy increases the incidence of toxicity compared with either agent alone.
Roni Meidan +5 more
wiley +1 more source
Transmissibility of intra-host hepatitis C virus variants
BMC Genomics, 2017 Background Intra-host hepatitis C virus (HCV) populations are genetically heterogeneous and organized in subpopulations. With the exception of blood transfusions, transmission of HCV occurs via a small number of genetic variants, the effect of which is ...
David S. Campo +3 more
doaj +1 more source
2021 National viral hepatitis progress report [PDF]
The National Viral Hepatitis Progress Report provides information on ten data indicators, providing an objective way to assess progress toward achieving key viral hepatitis goals.Publication date from document properties.FactSheet ...
core
Rab1A Promotes Hepatic Steatosis by Suppressing Mitophagy via the Raf‐1/ERK1/2/PINK1 Signaling Axis
Advanced Science, EarlyView.Why does fat accumulate in the liver? Our study reveals Rab1A as the molecular switch that silences the cell's mitochondrial cleanup crew. Turning Rab1A off reactivates mitophagy, clears excess fat, and reverses fatty liver disease in mice—offering a promising new therapeutic target for MASLD, a growing global health challenge.
Li Zhang +9 more
wiley +1 more source